Drugs / UFT
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06564844 Comparator | Oct 2024 → Jul 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | UFT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564844 ↗ |
| Route | Oral | “UFT Oral route of administration, Active Comparator” NCT06564844 ↗ |